Brings leading CNS products, including a product for the treatment of relapsing multiple sclerosis,to new territories

Dubai, UAE–1^st October, 2024 –Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launch of Neuraxpharm Middle Eastto cover the six members of the Gulf Cooperation Council (GCC) –United Arab Emirates (UAE), the Kingdom of Saudi Arabia,Bahrain, Kuwait, Oman and Qatar – as the Company continues its international expansion.